Salarius Pharmaceuticals (SLRX) Competitors

Salarius Pharmaceuticals (NASDAQ:SLRX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Is SLRX or SNOA more profitable?

Salarius Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat Salarius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Salarius Pharmaceuticals	N/A	-140.28%	-105.76%
Sonoma Pharmaceuticals	-26.82%	-68.98%	-26.39%

Do institutionals and insiders believe in SLRX or SNOA?

11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 1.4% of Salarius Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media refer more to SLRX or SNOA?

In the previous week, Salarius Pharmaceuticals had 2 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for Salarius Pharmaceuticals and 2 mentions for Sonoma Pharmaceuticals. Salarius Pharmaceuticals' average media sentiment score of 1.00 beat Sonoma Pharmaceuticals' score of 0.75 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Salarius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sonoma Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, SLRX or SNOA?

Salarius Pharmaceuticals has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.

Does the MarketBeat Community prefer SLRX or SNOA?

Sonoma Pharmaceuticals received 190 more outperform votes than Salarius Pharmaceuticals when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Salarius Pharmaceuticals	Outperform Votes 26 54.17%	Underperform Votes 22 45.83%
Sonoma Pharmaceuticals	Outperform Votes 216 67.50%	Underperform Votes 104 32.50%

Which has better valuation and earnings, SLRX or SNOA?

Sonoma Pharmaceuticals has higher revenue and earnings than Salarius Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Salarius Pharmaceuticals	N/A	N/A	-$12.54M	-$7.07	-0.13
Sonoma Pharmaceuticals	$13.97M	0.38	-$4.84M	-$4.02	-0.81

Summary

Sonoma Pharmaceuticals beats Salarius Pharmaceuticals on 9 of the 14 factors compared between the two stocks.